IBDEI1D9 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24207,1,1,0)
 ;;=1^446.3
 ;;^UTILITY(U,$J,358.3,24207,1,2,0)
 ;;=2^LETHAL MIDLINE GRANULOMA
 ;;^UTILITY(U,$J,358.3,24207,2)
 ;;=^52905
 ;;^UTILITY(U,$J,358.3,24208,0)
 ;;=446.1^^133^1475^10
 ;;^UTILITY(U,$J,358.3,24208,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24208,1,1,0)
 ;;=1^446.1
 ;;^UTILITY(U,$J,358.3,24208,1,2,0)
 ;;=2^MUCOCUTANEOUS LYMPH SYND (MCLS)
 ;;^UTILITY(U,$J,358.3,24208,2)
 ;;=^79494
 ;;^UTILITY(U,$J,358.3,24209,0)
 ;;=443.9^^133^1475^11
 ;;^UTILITY(U,$J,358.3,24209,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24209,1,1,0)
 ;;=1^443.9
 ;;^UTILITY(U,$J,358.3,24209,1,2,0)
 ;;=2^PERIPH VASCULAR DIS NOS
 ;;^UTILITY(U,$J,358.3,24209,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,24210,0)
 ;;=446.0^^133^1475^12
 ;;^UTILITY(U,$J,358.3,24210,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24210,1,1,0)
 ;;=1^446.0
 ;;^UTILITY(U,$J,358.3,24210,1,2,0)
 ;;=2^POLYARTERITIS NODOSA
 ;;^UTILITY(U,$J,358.3,24210,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,24211,0)
 ;;=710.4^^133^1475^13
 ;;^UTILITY(U,$J,358.3,24211,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24211,1,1,0)
 ;;=1^710.4
 ;;^UTILITY(U,$J,358.3,24211,1,2,0)
 ;;=2^POLYMYOSITIS
 ;;^UTILITY(U,$J,358.3,24211,2)
 ;;=^186822
 ;;^UTILITY(U,$J,358.3,24212,0)
 ;;=452.^^133^1475^14
 ;;^UTILITY(U,$J,358.3,24212,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24212,1,1,0)
 ;;=1^452.
 ;;^UTILITY(U,$J,358.3,24212,1,2,0)
 ;;=2^PORTAL VEIN THROMBOSIS
 ;;^UTILITY(U,$J,358.3,24212,2)
 ;;=^269815
 ;;^UTILITY(U,$J,358.3,24213,0)
 ;;=714.2^^133^1475^15
 ;;^UTILITY(U,$J,358.3,24213,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24213,1,1,0)
 ;;=1^714.2
 ;;^UTILITY(U,$J,358.3,24213,1,2,0)
 ;;=2^RHEUMATOID ARTHRITIS,SYSTEMIC
 ;;^UTILITY(U,$J,358.3,24213,2)
 ;;=^272111
 ;;^UTILITY(U,$J,358.3,24214,0)
 ;;=135.^^133^1475^16
 ;;^UTILITY(U,$J,358.3,24214,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24214,1,1,0)
 ;;=1^135.
 ;;^UTILITY(U,$J,358.3,24214,1,2,0)
 ;;=2^SARCOIDOSIS
 ;;^UTILITY(U,$J,358.3,24214,2)
 ;;=^107916
 ;;^UTILITY(U,$J,358.3,24215,0)
 ;;=710.0^^133^1475^17
 ;;^UTILITY(U,$J,358.3,24215,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24215,1,1,0)
 ;;=1^710.0
 ;;^UTILITY(U,$J,358.3,24215,1,2,0)
 ;;=2^SYST LUPUS ERYTHEMATOSIS
 ;;^UTILITY(U,$J,358.3,24215,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,24216,0)
 ;;=710.1^^133^1475^18
 ;;^UTILITY(U,$J,358.3,24216,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24216,1,1,0)
 ;;=1^710.1
 ;;^UTILITY(U,$J,358.3,24216,1,2,0)
 ;;=2^SYSTEMIC SCLEROSIS
 ;;^UTILITY(U,$J,358.3,24216,2)
 ;;=^108590
 ;;^UTILITY(U,$J,358.3,24217,0)
 ;;=446.7^^133^1475^19
 ;;^UTILITY(U,$J,358.3,24217,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24217,1,1,0)
 ;;=1^446.7
 ;;^UTILITY(U,$J,358.3,24217,1,2,0)
 ;;=2^TAKAYASU'S DISEASE
 ;;^UTILITY(U,$J,358.3,24217,2)
 ;;=^117141
 ;;^UTILITY(U,$J,358.3,24218,0)
 ;;=446.6^^133^1475^20
 ;;^UTILITY(U,$J,358.3,24218,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24218,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,24218,1,2,0)
 ;;=2^THROMBOT MICROANGIOPATHY
 ;;^UTILITY(U,$J,358.3,24218,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,24219,0)
 ;;=446.4^^133^1475^22
 ;;^UTILITY(U,$J,358.3,24219,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24219,1,1,0)
 ;;=1^446.4
 ;;^UTILITY(U,$J,358.3,24219,1,2,0)
 ;;=2^WEGENER'S GRANULOMATOSIS
 ;;^UTILITY(U,$J,358.3,24219,2)
 ;;=^127623
 ;;^UTILITY(U,$J,358.3,24220,0)
 ;;=444.9^^133^1475^4
 ;;^UTILITY(U,$J,358.3,24220,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24220,1,1,0)
 ;;=1^444.9
 ;;^UTILITY(U,$J,358.3,24220,1,2,0)
 ;;=2^ARTERIAL EMB/THROMBOSIS NEC
 ;;^UTILITY(U,$J,358.3,24220,2)
 ;;=^39452
 ;;
 ;;$END ROU IBDEI1D9
